By assessing the PD-L1 mRNA expression in plasma-derived EVs to monitor the treatment response in melanoma and non-small cell lung cancer, a study reported that PD-L1 levels decreased in patients who achieved partial or complete responses, while PD-L1 expression increased in patients who did not respond after ICI treatment (138). This evidence concerns the gene CD274 and non-small cell lung carcinoma.